Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses valuable endpoints beyond overall survival (OS) that can be used in ovarian cancer clinical trials.
Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer
July 22nd 2024An analysis from the innovaTV 301 showed that tisotumab vedotin in the second- and third-line bettered overall survival vs investigator’s choice of chemotherapy in patients with cervical cancer.
Read More